Advisory Services Network LLC Has $920,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Advisory Services Network LLC raised its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 296.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,993 shares of the company's stock after acquiring an additional 56,833 shares during the quarter. Advisory Services Network LLC's holdings in Elanco Animal Health were worth $920,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of ELAN. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health during the third quarter valued at $35,000. Jones Financial Companies Lllp raised its holdings in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares during the period. SRS Capital Advisors Inc. lifted its stake in Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares in the last quarter. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health in the fourth quarter worth about $61,000. Finally, Blue Trust Inc. increased its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ELAN shares. Barclays reduced their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. UBS Group decreased their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Morgan Stanley lowered their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler lowered their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Finally, Stifel Nicolaus reduced their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday, April 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Hold" and a consensus target price of $14.67.

Elanco Animal Health Stock Performance

ELAN traded up $0.34 during midday trading on Friday, reaching $8.44. The company's stock had a trading volume of 5,406,589 shares, compared to its average volume of 4,918,932. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The stock has a market cap of $4.19 billion, a P/E ratio of 21.11, a PEG ratio of 2.50 and a beta of 1.44. The company has a fifty day simple moving average of $10.26 and a 200 day simple moving average of $11.84. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm posted $0.08 EPS. The business's revenue for the quarter was down 1.4% compared to the same quarter last year. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.89% of the stock is owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.